Anavex Life Sciences (AVXL) Net Cash Flow (2010 - 2025)
Anavex Life Sciences recorded quarterly Net Cash Flow of $29.2 million in Q4 2025, up 1964.54% quarter-over-quarter from $1.4 million in Q3 2025, and up 355.63% year-over-year from $6.4 million in Q4 2024.
Anavex Life Sciences' Net Cash Flow history runs 16 years deep, the most recent figure standing at $29.2 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 355.63% year-over-year to $29.2 million; the TTM figure through Dec 2025 stood at $11.0 million (up 147.73% YoY), while the FY2025 annual figure was -$29.6 million, down 57.19% from the prior year.
- Net Cash Flow came in at $29.2 million for Q4 2025 at Anavex Life Sciences, up from $1.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $81.7 million in Q2 2021 to a low of -$14.6 million in Q2 2025.
- A 5-year average of $4.2 million and a median of -$2.4 million in 2021 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow soared 7636.27% in 2021 and slumped 2218.57% in 2025, its largest moves.
- Anavex Life Sciences' Net Cash Flow stood at -$961390.0 in 2021, then plunged by 475.83% to -$5.5 million in 2022, then slumped by 31.12% to -$7.3 million in 2023, then slumped by 57.21% to -$11.4 million in 2024, then jumped by 355.63% to $29.2 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $29.2 million, $1.4 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 29.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.17 Mn |
| Dec 31, 2025 | 29.17 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | -630,000.00 |
| Jun 30, 2024 | -630,000.00 |
| Mar 31, 2024 | -4.38 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Dec 31, 2023 | -7.26 Mn |
| Dec 31, 2023 | -7.26 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 9.85 Mn |
| Mar 31, 2023 | 9.85 Mn |
| Dec 31, 2022 | -5.54 Mn |
| Dec 31, 2022 | -5.54 Mn |
| Sep 30, 2022 | -4.04 Mn |
| Sep 30, 2022 | -4.04 Mn |
| Jun 30, 2022 | -143,204.00 |
| Jun 30, 2022 | -143,204.00 |
| Mar 31, 2022 | 2.20 Mn |
| Mar 31, 2022 | 2.20 Mn |
| Dec 31, 2021 | -961,390.00 |
| Dec 31, 2021 | -961,390.00 |
| Sep 30, 2021 | -5.45 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | 81.70 Mn |
| Jun 30, 2021 | 81.70 Mn |
| Mar 31, 2021 | 28.50 Mn |
| Mar 31, 2021 | 28.50 Mn |
| Dec 31, 2020 | 18.11 Mn |
| Dec 31, 2020 | 18.11 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | -895,352.00 |
| Mar 31, 2020 | -895,352.00 |
| Dec 31, 2019 | 5.27 Mn |
| Dec 31, 2019 | 5.27 Mn |
| Sep 30, 2019 | 936,424.00 |
| Sep 30, 2019 | 936,424.00 |
| Jun 30, 2019 | 1.79 Mn |
| Jun 30, 2019 | 1.79 Mn |
| Mar 31, 2019 | -1.26 Mn |
| Mar 31, 2019 | -1.26 Mn |
| Dec 31, 2018 | -2.22 Mn |
| Dec 31, 2018 | -2.22 Mn |
| Sep 30, 2018 | -2.90 Mn |
| Sep 30, 2018 | -2.90 Mn |
| Jun 30, 2018 | 171,008.00 |
| Jun 30, 2018 | 171,008.00 |
| Mar 31, 2018 | -2.39 Mn |
| Mar 31, 2018 | -2.39 Mn |
| Dec 31, 2017 | 608,387.00 |
| Dec 31, 2017 | 608,387.00 |
| Sep 30, 2017 | 2.65 Mn |
| Sep 30, 2017 | 2.65 Mn |
| Jun 30, 2017 | 1.44 Mn |
| Jun 30, 2017 | 1.44 Mn |
| Mar 31, 2017 | 2.19 Mn |
| Mar 31, 2017 | 2.19 Mn |
| Dec 31, 2016 | 11.97 Mn |
| Dec 31, 2016 | 11.97 Mn |
| Sep 30, 2016 | -540,226.00 |
| Sep 30, 2016 | -540,226.00 |
| Jun 30, 2016 | -2.22 Mn |
| Jun 30, 2016 | -2.22 Mn |
| Mar 31, 2016 | -1.90 Mn |
| Mar 31, 2016 | -1.90 Mn |
| Dec 31, 2015 | -1.44 Mn |
| Dec 31, 2015 | -1.44 Mn |
| Sep 30, 2015 | 7.33 Mn |
| Sep 30, 2015 | 7.33 Mn |
| Jun 30, 2015 | 1.65 Mn |
| Jun 30, 2015 | 1.65 Mn |
| Mar 31, 2015 | -670,281.00 |
| Mar 31, 2015 | -670,281.00 |
| Dec 31, 2014 | -281,214.00 |
| Dec 31, 2014 | -281,214.00 |
| Sep 30, 2014 | -917,543.00 |
| Sep 30, 2014 | -917,543.00 |
| Jun 30, 2014 | -1.01 Mn |
| Jun 30, 2014 | -1.01 Mn |
| Mar 31, 2014 | 9.10 Mn |
| Mar 31, 2014 | 9.10 Mn |
| Dec 31, 2013 | -249,147.00 |
| Dec 31, 2013 | -249,147.00 |
| Sep 30, 2013 | 343,429.00 |
| Sep 30, 2013 | 343,429.00 |
| Jun 30, 2013 | 1,158.00 |
| Jun 30, 2013 | 1,158.00 |
| Mar 31, 2013 | -79,302.00 |
| Mar 31, 2013 | -79,302.00 |
| Dec 31, 2012 | 68,427.00 |
| Dec 31, 2012 | 68,427.00 |
| Sep 30, 2012 | -6,833.00 |
| Sep 30, 2012 | -6,833.00 |
| Jun 30, 2012 | -160,452.00 |
| Jun 30, 2012 | -160,452.00 |
| Mar 31, 2012 | 169,568.00 |
| Mar 31, 2012 | 169,568.00 |
| Dec 31, 2011 | -125,623.00 |
| Dec 31, 2011 | -125,623.00 |
| Sep 30, 2011 | -1.09 Mn |
| Sep 30, 2011 | -1.09 Mn |
| Jun 30, 2011 | 1.22 Mn |
| Jun 30, 2011 | 1.22 Mn |
| Mar 31, 2011 | -420,142.00 |
| Mar 31, 2011 | -420,142.00 |
| Dec 31, 2010 | 159,114.00 |
| Dec 31, 2010 | 159,114.00 |
| Sep 30, 2010 | -1.19 Mn |
| Sep 30, 2010 | -1.19 Mn |